Library / Peptides / Skin & Hair / GHK-Cu
Emerging evidence · Grade B

GHK-Cu

GHK-Cu (Copper Peptide GHK-Cu)
Evidence
Emerging
Route
Topical or Subcutaneous injection
Frequency
Topical: 1-2x daily; Injection: 1x daily
Category
Skin & Hair
TL;DR
GHK-Cu is a naturally occurring copper-carrying peptide that declines as we age and plays important roles in skin repair, collagen production, and hair growth. Topical products containing it are popular and have some reasonable clinical evidence for improving skin quality and wound healing. Injectable or systemic use has an interesting theoretical basis from gene expression studies but lacks the clinical trials needed to confirm safety and efficacy in humans.
Part 01 · How it works

Mechanism.

GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys) first isolated from human plasma in 1973 by Loren Pickart. It is present in blood, saliva, and urine and declines with age. GHK-Cu has broad biological activities including promotion of wound healing, collagen synthesis, inflammation-modulating activity, antioxidant effects, and hair follicle stimulation. It is used extensively in cosmeceuticals and has emerging data supporting systemic anti-aging effects.

GHK-Cu is like a master renovation coordinator for aging tissue. It simultaneously orders new building materials (collagen), stops the demolition crew (MMP inhibition), brings in new water pipes (angiogenesis), and sends renovation instructions to the blueprints (gene expression changes). It does this in skin, scalp, wounds, and potentially throughout the body.

Mechanism · technical
GHK-Cu binds copper (Cu2+) in a tight complex and acts on multiple pathways: it activates TGF-beta signaling to stimulate collagen I and III, fibronectin, and decorin synthesis; it inhibits MMP activity, reducing collagen degradation; it promotes VEGF-driven angiogenesis; it modulates gene expression of over 4,000 human genes (including upregulating DNA repair and anti-aging genes while downregulating inflammatory and oncogenic pathways per Pickart's genomic analyses); and it activates Wnt/beta-catenin signaling in hair follicles, extending anagen phase.
Part 02 · Dosing & administration

How it's taken.

Values below describe how GHK-Cu has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose
1-2 mg/mL topical; 50-200 mcg subcutaneous (off-label)
Topical or Subcutaneous injection · Topical: 1-2x daily; Injection: 1x daily
Duration
Topical: ongoing; Injection: 4-8 weeks

Most evidence is for topical use in cosmeceuticals. Subcutaneous injection protocols are based on limited clinical data. GHK-Cu is naturally present in human plasma.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator
Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Reported side effects
Topical GHK-Cu is generally very well-tolerated. Mild skin irritation possible at high concentrations. Green-blue discoloration of skin at application site with very high doses (copper pigment). Systemic injectable GHK-Cu: safety data are very limited. Theoretical risk of copper toxicity with excessive systemic administration.
Absolute · do not use
×
Known hypersensitivity to GHK-Cu, copper peptides, or any component
×
Wilson's disease or copper metabolism disorders
×
Pregnancy or breastfeeding
×
Children under 18
×
Active skin cancer at application site (may promote tissue remodeling)
Interactions
Copper chelators (penicillamine, trientine)
May reduce efficacy of copper peptide by chelating copper component
Moderate
Topical retinoids
Combined use may increase skin irritation; stagger application times
Minor
Topical acids (AHA, BHA, vitamin C at low pH)
Acidic pH may degrade peptide; separate application times by 30 minutes
Minor
Labs to monitor
Serum Copper
Baseline and every 3 months
Monitor copper levels with copper peptide use
Ceruloplasmin
Baseline and every 3 months
Copper metabolism assessment
Zinc Level
Baseline and every 3 months
Copper supplementation can deplete zinc
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver function (copper is hepatically metabolized)
Part 04 · Evidence

How strong is the evidence?

Scores derived from rating, indexed studies, regulatory status, and catalogued safety data for this peptide. Curated per-peptide scoring replaces this when available.

66
Grade C
Grade C. Signal is real but maturing. Treat results as directional until larger or independent replications land.
Clinical efficacy
Emerging signal across multiple indexed studies; effect sizes still firming up.
68
Study quality
4 indexed studies in our dataset. Designs vary — see Research log for per-study grades.
87
Regulatory clarity
Not approved; availability is compounding/research-only.
45
Safety profile
Based on 5 documented contraindications, 3 interactions, 4 lab checkpoints.
84
Long-term data
Long-horizon data not yet available outside research settings.
48
Part 05 · Research log

Every study we cite.

Each study with its published finding and a plain-language note on limitations or funding.

01
2009
0
GHK-Cu stimulates collagen synthesis and improves skin parameters: double-blind trial
A double-blind, placebo-controlled study showed topical GHK-Cu significantly improved skin density, skin thickness, and collagen content compared to placebo and vitamin C after 12 weeks of twice-daily application.
Small sample size; industry-connected funding. Validated outcome measures used (ultrasound, biopsy).
PMID 19337170 ↗
02
2015
0
GHK-Cu in wound healing: clinical evaluation in dermal wounds
GHK-Cu topical application significantly accelerated wound re-epithelialization, reduced wound area, and improved final scar appearance compared to standard wound care in a clinical study.
Limited sample size, single-center. Wound healing studies have inherent variability based on wound type and patient factors.
PMID 26290965 ↗
03
2012
0
GHK-Cu modulates gene expression in human dermal fibroblasts
Microarray analysis revealed GHK-Cu modulated over 4,000 genes in human fibroblasts, upregulating collagen synthesis, DNA repair, and inflammation-modulating pathways while downregulating genes associated with senescence and cancer.
In vitro study. Gene expression changes in cell culture do not directly predict clinical outcomes. Pickart group has a financial interest in GHK-Cu.
PMID 22291164 ↗
04
2007
0
GHK and hair growth: effects on human hair follicles in vitro and in vivo
GHK-Cu extended anagen phase in vitro and was associated with improved hair density and thickness in a small clinical study of androgenetic alopecia patients.
Small clinical cohort. No sham-controlled arm. Hair follicle culture findings require validation in larger trials.
PMID 17373704 ↗
Part 06 · Cost & access

Where you can get it.

Regulatory status
Legal as a cosmetic ingredient globally (topical formulations). No FDA approval as a drug. Sold as a cosmeceutical active in OTC products. Compounded injectable GHK-Cu is available through research peptide suppliers; not FDA-regulated for this purpose. WADA: not currently listed as banned.
The Peptide Column takes no affiliate commission from any source.
Part 07 · Your appointment

Questions to bring.

01
For my degree of skin aging or hair thinning, is topical GHK-Cu sufficient or would injectable/systemic GHK-Cu provide additional benefit?
02
Are there any concerns about systemic copper accumulation with long-term use, particularly if I take copper-containing supplements?
03
How does GHK-Cu compare to retinoids, peptide growth factors, or platelet-rich plasma for my specific skin concern?
04
Is there any risk of GHK-Cu stimulating tumor growth given its pro-angiogenic and proliferative effects?